Rubin, D. T. Et Al. 2025. Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. LANCET , vol.405, no.10472 , 33-49.

Rubin, D. T., Allegretti, J. R., Panes, J., Shipitofsky, N., Yarandi, S. S., Huang, K. G., ... Germinaro, M.(2025). Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. LANCET , vol.405, no.10472, 33-49.

Rubin, David Et Al. "Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies," LANCET , vol.405, no.10472, 33-49, 2025

Rubin, David T. Et Al. "Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies." LANCET , vol.405, no.10472, pp.33-49, 2025

Rubin, D. T. Et Al. (2025) . "Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies." LANCET , vol.405, no.10472, pp.33-49.

@article{article, author={David T. Rubin Et Al. }, title={Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies}, journal={LANCET}, year=2025, pages={33-49} }